Company Filing History:
Years Active: 2025
Title: Elisa Liardo: Innovator in Targeted Protein Degradation
Introduction
Elisa Liardo is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of targeted protein degradation, particularly in relation to the NIMA Related Kinase 7 (NEK7). Her innovative work has the potential to address various disorders and diseases associated with NLRP3 inflammasome activation.
Latest Patents
Elisa Liardo holds 1 patent for her groundbreaking work on chemical entities that degrade and modulate NEK7. This patent outlines the use of these chemical entities for treating a range of disorders, including autoinflammatory and autoimmune diseases, neurodegenerative conditions, cardiovascular and metabolic disorders, fibrotic diseases, and eye disorders. The patent emphasizes the direct targeting of NEK7, which is believed to alter the inflammatory response modulated by the NLRP3 inflammasome.
Career Highlights
Elisa Liardo is currently associated with Monte Rosa Therapeutics AG, where she continues to advance her research and development efforts. Her work is pivotal in the quest for new therapeutic strategies to combat complex diseases.
Collaborations
Elisa collaborates with notable colleagues, including Laura Ann McAllister and Bernhard Fasching, who contribute to her innovative projects and research initiatives.
Conclusion
Elisa Liardo's contributions to targeted protein degradation represent a significant advancement in medical research. Her innovative approach has the potential to lead to new treatments for a variety of serious health conditions.